Literature DB >> 10416378

Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees.

M Esumi1, T Rikihisa, S Nishimura, J Goto, K Mizuno, Y H Zhou, T Shikata.   

Abstract

A chimpanzee was immunized with two recombinant envelope glycoproteins E1 and E2 of hepatitis C virus (HCV), strain HCV-N2, and the hypervariable region 1 (HVR1) peptides of a different isolate, HCV-#6, then received an intravenous inoculation of 10 chimpanzee infectious doses of HCV-#6. With high humoral immune response against E1 and E2 but a low response against HVR1, the vaccinee became infected with the HCV. However, after increasing the titer of anti-HVR1 against HCV-#6, the vaccinee showed protection. Neutralization of HCV-#6 with the antiserum from this protected vaccinee was achieved by inoculation of this mixture into another chimpanzee. These results suggest that vaccination with a peptide-vaccine of homologous HVR1 is effective in the chimpanzee.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416378     DOI: 10.1007/s007050050559

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  17 in total

1.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

2.  Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.

Authors:  Heather J Ezelle; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1.

Authors:  C Li; D Candotti; J P Allain
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 5.  Update on chronic viral hepatitis.

Authors:  K Walsh; G J Alexander
Journal:  Postgrad Med J       Date:  2001-08       Impact factor: 2.401

Review 6.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

7.  Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes.

Authors:  H J Netter; T B Macnaughton; W P Woo; R Tindle; E J Gowans
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

9.  Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.

Authors:  Alexander W Tarr; Richard A Urbanowicz; Mohamed R Hamed; Anna Albecka; C Patrick McClure; Richard J P Brown; William L Irving; Jean Dubuisson; Jonathan K Ball
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

Review 10.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.